

Note

Synthetic access to all four stereoisomers of oxetin

Ahmad F Kassir, Sherif Shaban Ragab, Thao Anh Minh Nguyen, Florence Charnay-Pouget, Régis Guillot, Marie-Christine Scherrmann, Thomas Boddaert, and David J. Aitken J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.6b01795 • Publication Date (Web): 23 Sep 2016 Downloaded from http://pubs.acs.org on September 29, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Synthetic access to all four stereoisomers of oxetin

Ahmad F. Kassir,[†] Sherif S. Ragab,^{†,†} Thao A. M. Nguyen,[†] Florence Charnay-Pouget,[†] Régis Guillot,^{||} Marie-Christine Scherrmann,[†] Thomas Boddaert[†] and David J. Aitken^{†,*}

⁺ CP3A Organic Synthesis Group, ICMMO, CNRS UMR 8182, Université Paris Sud, Université Paris Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France.

[†] Photochemistry Department, Chemical Industries Research Division, National Research Centre, P.O. Box 12622, Dokki, Giza, Egypt.

^I Services Communs, ICMMO, CNRS UMR 8182, Université Paris Sud, Université Paris Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France.

TOC graphic & Abstract



A short synthesis of all four stereoisomers of 3-amino-2-oxetanecarboxylic acid (oxetin) is described. The oxetane core is built using a Paternò-Büchi photochemical [2+2]-cycloaddition; from the key intermediates, complementary resolution protocols provide access to enantiomerically pure oxetin and *epi*-oxetin on gram-scale.

The β -aminoacid (2*R*,3*S*)-*cis*-3-amino-2-oxetanecarboxylic acid, named oxetin, was first isolated by Ōmura *et al.* in 1984 from the soil bacterium *Streptomyces sp.* OM-2317 (Figure 1). It showed herbicidal activity through inhibition of plant glutamine synthetase and exhibited anti-bacterial activity against *Bacillus subtilis, Piriculaia oryzae* and other microorganisms.¹ The same authors described a synthesis of (2*R*,3*S*)-oxetin from *D*-glucose which also provided the three other stereoisomers, in more than ten steps for each stereoisomer and a combined overall yield of 7%.² In 1997, Bach and Schröder applied the Paternò-Büchi [2+2]-photocycloaddition reaction to the synthesis of oxetin; this synthesis required only four steps and provided oxetin in 14% overall yield, but only the racemic *cis* stereoisomer was obtained.³ More recently, Blauvelt and Howell investigated an approach to oxetin starting from *L*-serine; the unexpected diastereoselectivity observed during the reduction of a spiroepoxide intermediate led to a single enantiomer of the *trans* diastereoisomer, *epi*-oxetin, in ten steps and 1.5% overall yield.⁴

(2 <i>R</i> ,3 <i>S</i>)-0	axetin	(2S,3R))-oxetin	(2R,3 <i>R</i>)-	epi-oxetin	(2 <i>S</i> ,3 <i>S</i>)⊣	epi-oxetin
(+)-1		(-)	-1a	(+)-1b	(−))-1b
	со ₂ н	H ₂ N``	-о _, _′́со₂н	н ₂ N`	-о Со ₂ н	H ₂ N	-0 ⊥, ́′со₂н

Figure 1 The four stereoisomers of oxetin

Functionalized oxetanes are important building blocks for the synthesis of complex molecules and drug discovery,⁵ and as a cyclic β -aminoacid, oxetin has further potential for inclusion in biologically active peptides.^{6,7,8} These observations, alongside the initial reports of biological activity for natural (2*R*,3*S*)-oxetin, warrant further development of a short, reliable access to all stereoisomers on exploitable scale. A comparison of the three previous studies suggested to us that the Paternò-Büchi reaction was the most promising strategy;^{9,10,11} we describe herein its successful application, employing an *N*-formyl enamine **2**¹² and a glyoxylate ester **3**,¹³ to provide to the core oxetane skeleton **4**, from which the requisite targets are obtained as single enantiomers on gram-scale (Scheme 1).



We began by investigating the influence of the alkyl moiety of the glyoxylate ester on the course of the Paternò-Büchi reaction. To this end we prepared the *n*-butyl, methyl, and *t*-butyl esters (**3a-c**): the former two were obtained by periodate-mediated oxidative cleavage of the corresponding dialkyl tartrates,¹⁴ the latter by ozonolysis of *tert*-butyl acrylate.¹⁵ These compounds had to be freshly distilled from P_2O_5 immediately before use; even so, their marked propensity for hydrate or hemiacetal formation imposed the use of a dry aprotic solvent in the photochemical reaction. Our first choice of enamine partner was *N*-vinylformamide **2a**, a stable, commercially available material.

Freshly distilled glyoxylates **3a-c** in anhydrous acetonitrile (75 mM) were each engaged in a [2+2]photocycloaddition reaction with two equivalents of **2a** in a Pyrex[®] reaction vessel (200 mL) using a 400 W Hg-vapor lamp for 24 h, to furnish oxetanes **5-7** in 34-37% yields (Table 1). In each case, complete regioselectivity was observed while the *cis/trans* ratio was close to 1:1; in no case could the **a/b** diastereoisomers be separated on a preparative scale. The moderate efficiency is typical of Paternò-Büchi reactions where the carbonyl reagent is not an aromatic aldehyde and is quite acceptable given the intrinsic low stability of glyoxylates and their sensitivity to photodecomposition.¹⁶ The high regioselectivity and poor diastereoselectivity are in agreement with mechanistic arguments on the Paternò-Büchi reaction.¹⁷ Most literature precedents featuring a glyoxylate in Paternò-Büchi reactions employ the *n*-butyl ester **3a**;¹³ we likewise retained it for subsequent studies.

Table 1 Influence of the nature of the glyoxylate ester

OHC (2 equiv.) 2a	+ CO ₂ F	hv R CH ₃ CN (75 mM) 24 h, r.t	0+C-1 ← 02R + (±)-5a (±)-6a (±)-7a	OHC~U (±)-5b (±)-6b (±)-7b
Entry	R	Glyoxylate	Ratio a/b ^a	Yield (%)⁵
1	<i>n</i> -Bu	3a	5a/5b 51:49	37
2	Me	3b	6a/6b 50:50	37
3	t-Bu	3c	7a/7b 54:46 ^c	34

^aRatio **a/b** determined from the crude ¹H NMR spectra. ^bIsolated yield of inseparable diastereoisomeric mixture. ^cDiastereoisomers were not unambiguously assigned.

The influence of concentration and scale were investigated next (Table 2). Whereas concentration had no effect on the efficiency (entries 1-3), working on a larger scale was perceptibly beneficial (entries 4, 5). The best result was obtained by employing **3a** (100 mM) and two equivalents of **2a** in acetonitrile in a large Pyrex[®] reaction vessel (1 L) using a 400 W Hg-vapor lamp, which gave the photoadducts **5a/5b** in 46% yield on multigram-scale (9.3 g, 46 mmol). The same reaction was also examined using a Rayonet apparatus, but the efficiency was significantly lower (entry 6).

Table 2 Scaling of the reaction between 2a and 3a

OHC (2 equi 2a	↓ + ↓ CO; iv.) 3a	Bu CH ₃ CN 24 h, r.t	онс ₋ (±)-5а	+ OHC_H (±)-5t
Entry	Conc.	Scale	Ratio 5a/5b ^ª	Yield (%) ^b
1	75 mM	200 mL	51:49	37
2	20 mM	200 mL	47:53	33
3	150 mM	200 mL	51:49	34
4	75 mM	1000 mL	50:50	43
5	100 mM	1000 mL	50:50	46
6°	75 mM	100 mL	48:52	19

^a Determined from crude ¹H NMR spectra. ^b Isolated yield of diastereoisomeric mixture. ^c Performed using Rayonet apparatus RPR-200.

Four-membered ring β -aminoacids are susceptible to ring opening when the amine function is not deactivated by a protecting group.¹⁸ To facilitate subsequent manipulations, we decided to introduced a carbamate protecting group onto **5a/5b** in place of the formyl group. The **5a/5b** mixture was treated with Boc₂O to provide the corresponding derivatives **8a** and **8b** in 85% yield up to 10 g scale; significantly, these two diastereoisomers could be separated conveniently by column chromatography

The Journal of Organic Chemistry

(Scheme 2). Thus, starting from *N*-vinylformamide **2a** and glyoxylate **3a**, the two-step protocol provided both **8a** and **8b** as single diastereoisomers in 39% combined overall yield. Each derivative was engaged in a one-pot selective deprotection sequence employing K_2CO_3 in methanol to give racemic Bocprotected (±)-oxetin **9a** and (±)-*epi*-oxetin **9b** in 97% and 96% yields, respectively (Scheme 2).





Here it became evident that we should consider an alternative pathway to **8a** and **8b**, using *N*-Boc-*N*-vinylformamide **2b** as a Paternò-Büchi partner; this substrate was prepared in 93% yield from *N*-vinylformamide **2a** upon treatment with Boc₂O and was evaluated in the photochemical reaction with **3a** (Table 3). The first experiment, conducted at 75 mM, gave only 13% combined yield of adducts **8a/8b** (entry 1). Further investigation (entries 2,3) revealed that a high **2b** concentration was deleterious to the efficiency of the reaction and that the best yield was obtained when the concentration of **3a** was 20 mM (entry 3). This result could be reproduced on a larger scale (1 L; entry 4). On the premise that photochemical degradation of reagent **2b** might be occurring during the reaction time,¹⁹ an experiment was conducted in which the concentration of **2b** (75 mM) represented a 5-fold excess with respect to **3a** (entry 5); in this case, the reaction was indeed more efficient and **8a/8b** was obtained in 53% yield. In the course of these investigations, the *cis/trans* ratio remained close to 1:1. The best result, obtained at 20 mM on large scale (1 L), gave both **8a** and **8b** as single diastereoisomers in 45% yield. This approach represents a valid alternative for access to **8a** and **8b**; starting from *N*-vinylformamide **2a**, the two-step protocol is slightly more efficient than the first route (42% combined overall yield) but requires higher dilution for the photochemical step.

Table 3 Scaling the reaction between 2b and 3a

|| °

Γî

2b Box (2 equ	c 3a iv.)	Bu CH ₈ CN 24 h, r.t	OHC CO ₂ Bu Boc Sec (±)-8a diast	+ OHC N CO Boc sparable eroisomers (±)-8b	O ₂ B
Entry	Conc.	Scale	Ratio 8a/8b ^ª	Yield (%) ^b	
1	75 mM	200 mL	48:52	13	
2	40 mM	200 mL	44:56	18	
3	20 mM	200 mL	43:57	45	
4	20 mM	1000 mL	48:52	45	
5 °	75 mM	200 mL	50:50	53	

The Journal of Organic Chemistry

^aRatio determined from crude ¹H NMR spectra. ^bCombined yield of isolated diastereoisomers. ^cReaction performed using 5 equiv. of **2b**.

For completeness, we examined a third enamine substrate, N-vinyl tert-butyl carbamate 2c, obtained in 98% yield by selective deformylation of **2b** using NaOH in THF. The Paternò-Büchi reaction of **2c** in acetonitrile (75 mM, 200 mL scale) with two equivalents of 3a gave 10a and 10b in 41% yield as an inseparable 1:1 diastereoisomeric mixture (Scheme 3). Since this route offered no advantage with respect to the previous series, it was not pursued.



Scheme 3

We turned our attention to the matter of resolution. Noting previous successes with chiral non-racemic oxazolidinones as resolving agents for cyclic β -aminoacids,²⁰ we screened three such auxiliaries for the chiral derivatization of 9a and 9b (Table 4). Standard peptide coupling reagents were unproductive so we applied more stringent conditions: the acid function of **9a** or **9b** was activated using pivaloyl chloride and then treated with the lithium salt of the oxazolidinone **11a-c**; highest yields were obtained using an excess of both of these reagents.

After optimization, (±)-N-Boc-oxetin 9a and oxazolidinone 11a gave diastereoisomers 12aa1 and 12aa2 in 45% combined yield, which equated to 52% yield taking recovered starting material 9a into account (entry 1). The modest yield was compounded by the impracticality of the separation of the two diastereoisomers and unreacted 11a. With oxazolidinone 11b, the yield and ease of separation improved slightly (entry 2). Oxazolidinone **11c** gave better results: diastereoisomers **12ac1** and **12ac2** were obtained in 69% combined yield (81% based on recovered **9a**) and were easily separated by chromatography (entry 3).

With (±)-N-Boc-epi-oxetin 9b, oxazolidinone 11a provided diastereoisomers 12ba1 and 12ba2 in 66% combined yield (86% yield based on recovered 9b) and separation by chromatography was satisfactory (entry 4). This turned out to be the most practical system, for the corresponding derivatizations using oxazolidinones **11b** and **11c** gave lower yields and poorer separations (entries 5,6).

Table 4 Chiral resolution

(±)-9a -	(a), (b) ► B	OCHN 00	< + BocHN ¹	0 	
(±)-9b -	(a), (b) ► B	OCHN ^V	< + BocHN		
Conditions (a) PivCl (1 NEt ₃ (1.2 e (b) LiOx* (1	: .5 eq), q), THF, 0 °C; I.6 eq),	LIOX* = LIN	DBn Me		
THF, -78 °(5	0 1	1a ⁰ 11b	0 11c	
Entry	Sub. 9	LiOx 11	Product	Separation ^a	Yield (%) ^b
Entry 1	Sub. 9 9a	LiOx 11 11a	1a 11b Product 12aa1/2	Separation ^a Poor	Yield (%) ^b 45 (52)
Entry 1 2	Sub. 9 9a	LiOx 11 11a 11b	Product 12aa1/2 12ab1/2	Separation ^a Poor Good	Yield (%) ^b 45 (52) 51 ^c (57)
1 2 3	Sub. 9 9a	LiOx 11 11a 11b 11c	Product 12aa1/2 12ab1/2 12ac1/2	Separation ^a Poor Good Excellent	Yield (%) ^b 45 (52) 51 ^c (57) 69 (81)
Entry 1 2 3 4	Sub. 9 9a 9b	LiOx 11 11a 11b 11c 11a	Image: Non-Struct (Non-Struct Non-Struct No	Separation ^a Poor Good Excellent Good	Yield (%) ^b 45 (52) 51 ^c (57) 69 (81) 66 (86)
THF, -78 °C Entry 1 2 3 4 5	Sub. 9 9a 9b	LiOx 11 11a 11b 11c 11a 11b	Product 12aa1/2 12ab1/2 12ac1/2 12ba1/2 12ba1/2 12bb1/2	Separation ^a Poor Good Excellent Good Fair	Yield (%) ^b 45 (52) 51 ^c (57) 69 (81) 66 (86) 34 (44)

^aEase of preparative chromatographic separation of diastereoisomers **12** and unreacted **11**. ^bCombined yield of diastereoisomers; in parentheses, yields based on recovered **9**.

An important spin-off from the above endeavors was the isolation of crystals of derivatives **12ab2** and **12bb2** which were suitable for X-ray diffraction analysis, thus confirming the molecular structures and revealing the absolute configurations of the oxetane stereogenic centers (Figure 2).



Figure 2 X-ray structures of 12ab2 and 12bb2.

Enantiomerically pure *N*-Boc-oxetins (2*R*,3*S*)-**9a** and (2*S*,3*R*)-**9a** were obtained in high yields by $LiOH/H_2O_2$ hydrolysis of derivatives **12ac1** and **12ac2**, respectively, in a procedure which allowed recovery and recycling of oxazolidinone **11c**. Similarly, derivatives **12ba1** and **12ba2** provided *N*-Boc-*epi*-oxetins (2*R*,3*R*)-**9b** and (2*S*,3*S*)-**9b** as well as recovered oxazolidinone **11a**. The absolute configurations of these compounds were deduced by conducting analogous hydrolyses on **12ab2**, which gave (+)-(2*S*,3*R*)-**9a**, and **12bb2**, which gave (-)-(2*S*,3*S*)-**9b**. Each *N*-Boc- β -aminoacid was deprotected in excellent yield using TFA to complete the stated objectives and provide all four oxetin and *epi*-oxetin stereoisomers:





Conditions: (a) LiOH, H₂O₂ THF/H₂O (4:1), 2 h, 0°C. (b) TFA, CH₂Cl₂, 3 h, r.t. then Dowex, NH₄OH

Scheme 4

Chiral derivatization may not always be a favored option so we considered an alternative access to single oxetin stereoisomers using chiral HPLC. Racemates (\pm)-**9a** and (\pm)-**9b** (Scheme 2) were extensively degraded regardless of the nature of the stationary phase. Pleasingly, however, each racemate (\pm)-**8a** and (\pm)-**8b** (Table 3) was separated on a lux cellulose column with good selectivity ($\alpha = 1.63$ for **8a** and $\alpha = 1.25$ for **8b**) providing ~1 g of each enantiomer (ee >99% by chiral HPLC analysis) in 12 h using an automatic injection sequence. We verified that the one-pot selective deprotection protocol proceeded without incident, and obtained the expected single enantiomers of *N*-Boc-oxetin **9a** and *N*-Boc-*epi*-oxetin **9b** in high yields on gram-scale (Scheme 5).



Scheme 5

In summary, an expedient access to all stereoisomers of oxetin on gram-scale has thus been established *via* a Paternò-Büchi synthetic strategy starting from **2b** and **3a**. For any individual oxetin target, the protocol requires 5 synthetic steps and 2 chromatographic separations if a resolving agent is employed, or just 3 steps plus one chromatographic separation and one chiral HPLC operation if this latter technique is preferred. The overall yield for a single isomer is ~8% in the former case and ~11% in the latter.

Experimental Section

General Experimental: All reagents and solvents were of commercial grade and were used without further purification, with the exception of MeCN which was distilled from P_2O_5 , *n*-BuOH which was distilled from MgSO₄, CH₂Cl₂ which was dried over activated alumina, and THF which was distilled from sodium/benzophenone. Flash chromatography was performed on columns of silica gel ($35-70 \mu m$). Analytical thin-layer chromatography was carried out on commercial 0.25 mm silica gel plates which were visualized by UV fluorescence at 254 nm then revealed using a phosphomolybdic acid solution (10% in EtOH) or a ninhydrin solution (0.3% in *n*-BuOH). Retention factors (R_f) are given for such TLC analyses. Melting points were obtained in open capillary tubes and are uncorrected. Optical rotations were measured using a 10 cm quartz cell; values for $[\alpha]_D^T$ were obtained with the D-line of sodium at the indicated temperature T, using solutions of concentration (c) in units of g·100 mL⁻¹. Fourier-transform Infrared (IR) spectra were recorded for neat samples using an ATR diamond accessory; maximum absorbances (v) are given in cm⁻¹. Nuclear magnetic resonance (NMR) data were acquired on a spectrometer operating at 400/360/300/250 MHz for ¹H, and at 90/75/63 MHz for ¹³C. Chemical shifts (δ) are reported in ppm with respect to tetramethylsilane (δ = 0 ppm). Splitting patterns for ¹H NMR and ¹³C NMR signals are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintuplet), broad singlet (br. s) or m (multiplet). Coupling constants (J) are reported in Hz. High-resolution mass spectrometry (HRMS) data were recorded using on a spectrometer equipped with an electrospray ionization source either in positive or negative mode as appropriate, with a tandem Q-TOF analyzer. Preparative HPLC purification of the two enantiomers of the compounds 8a and 8b was carried out on a commercial apparatus equipped with semi-preparative auto-sampler and collector accessories. All solvents were HPLC grade and were filtered through a 0.45 µm PTFE membrane. Injected solutions were filtered through a 0.22 µm PTFE membrane. Methyl glyoxylate **3b**,¹⁴ *tert*-butyl glyoxylate **3c**,14 oxazolidin-2-one **11a**^{21a} and oxazolidin-2-one **11b**^{21b} were prepared according to literature procedures.

General Procedure A for the Paternò-Büchi reaction

A solution of glyoxylate **3** (1 equiv.) and enamine derivative **2** (2 equiv.) in MeCN was placed in a cylindrical immersion photochemical reactor and degassed with an argon stream for 30 min. The solution was irradiated for 24 h with a 400 W medium-pressure Hg lamp fitted with a Pyrex[®] filter and a water-cooling jacket. The solution was then evaporated under reduced pressure to give the crude product which was purified by flash chromatography to afford the requisite product.

General Procedure B for the deformylation/saponification sequence

To an ice-cold solution of compound **8** (1 equiv.) in MeOH (13 mL/mmol) was added K_2CO_3 (3 equiv.). The reaction mixture was stirred at 0 °C for 10 min then at room temperature for 2 h. Water (6

Page 9 of 22

The Journal of Organic Chemistry

mL/mmol) was added and the reaction was further stirred at room temperature for 1 h. MeOH was evaporated under reduced pressure and the remaining aqueous solution was washed with EtOAc (3×6 mL/mmol). The aqueous phase was then acidified with KHSO₄ and extracted with EtOAc (4×6 mL/mmol). The combined organic phases were dried over Na₂SO₄, filtrated and concentrated under reduced pressure to give product **9**.

General procedure C for oxazolidinone coupling

To a cold (–78 °C) solution of racemic compound **9** (1 equiv.) and triethylamine (1.2 equiv.) in THF (10 mL/mmol) was added pivaloyl chloride (1.5 equiv.) dropwise. The mixture was stirred at 0 °C for 1 h to form the mixed anhydride, and then cooled to –78 °C. In a separate flask, a cold (–40 °C) solution of oxazolidinone **11** (1.6 equiv.) in THF (5 mL/mmol) was treated with a hexane solution of *n*-BuLi (1.6 equiv.) and stirred for 25 min. The resulting solution was cooled to –78 °C and added by rapid cannulation to the cooled (–78 °C) solution of the mixed anhydride. Residual metalated oxazolidinone was taken up by rinsing with dry THF and added to the cooled reaction mixture. After 2 h, the reaction mixture was quenched at –78 °C by addition of a saturated aqueous solution of NaHCO₃ then allowed to warm to room temperature. THF was removed under reduced pressure and the remaining aqueous solution was extracted with CH₂Cl₂ (3 × 15 mL/mmol). The combined organic phases were washed with a saturated aqueous solution of NaHCO₃ (15 mL/mmol) then brine (15 mL/mmol), dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography to afford the two diastereoisomers **12**. Unreacted **9** was recovered from the basic aqueous phase by acidification then extraction with CH₂Cl₂.

General procedure D for oxazolidinone cleavage

To an ice-cold solution of the indicated compound **12** (1 equiv.) in a 1:4 mixture of water and THF (25 mL/mmol) was added a 35% w/w solution of H_2O_2 (2 equiv.). The resulting mixture was stirred at 0 °C for 5 min then a solution of LiOH·H₂O (2 equiv.) in water (6 mL/mmol) was added. The mixture was stirred at 0 °C for 2 h then a saturated aqueous solution of Na₂SO₃ (14 mL/mmol) and a saturated aqueous solution of NaHCO₃ (14 mL/mmol) were added successively. THF was removed under reduced pressure and the residual aqueous solution was washed with CH_2Cl_2 to remove and recycled the chiral auxiliary. The aqueous solution was then acidified to pH 1 with an aqueous solution of KHSO₄ (1 M) and extracted with CH_2Cl_2 (3 × 10 ml/mmol). The combined organic extracts were dried over Na₂SO₄, filtrated and evaporated under reduced pressure to give non-racemic product **9**.

General procedure E for Boc group removal

To a solution of the indicated compound **9** (1 equiv.) in CH_2Cl_2 (15 mL/mmol) under argon was added trifluoroacetic acid (15 equiv.). The solution was stirred for 3 h then reaction mixture was concentrated under reduced pressure. The residue was applied to a column of Dowex[®] 50W-X8 cation exchange resin (200 mesh) and eluted using 1 M NH₄OH to give the target amino acid.

Di-n-butyl tartrate

To a mixture of tartaric acid (118 g, 0.78 mol, 1 equiv.) and *n*-BuOH (350 mL, 3.93 mol, 5 equiv.) was added TMSCI (200 mL, 1.56 mol, 2 equiv.). The reaction mixture was refluxed for 6 h and then cooled to room temperature. Excess *n*-BuOH and TMSCI were removed under reduced pressure and the oily residue was distilled under reduced pressure (0.45 mm Hg) at 130 °C to give the expected product as a colorless oil (121 g, 59%). R_f (25:75 EtOAc/Petroleum ether): 0.60; IR v 3487, 2961, 2935, 2875, 1738, 1243, 1124, 1086; ¹H NMR (250 MHz, CDCl₃) δ 4.48 (s, 2H), 4.18 (t, *J* = 6.6 Hz, 4H), 3.53 (s, 2H), 1.67-1.53 (m, 4H), 1.41-1.25 (m, 4H), 0.87 (t, *J* = 7.3 Hz, 6H), (lit.^{14a}); ¹³C NMR (63 MHz, CDCl₃) δ 171.6 (2C), 72.2 (2CH), 66.0 (2CH₂), 30.5 (2CH₂), 18.9 (2CH₂), 13.5 (2CH₃), (lit.^{14a}); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₂H₂₂O₆Na 285.1314; Found 285.1302.

n-Butyl glyoxylate 3a

To a solution of di-*n*-butyl tartrate (31.5 g, 120 mmol, 1 equiv.) in Et₂O (1 L) at 0 °C under argon was added periodic acid dihydrate (27.3 g, 120 mmol, 1 equiv.) in portions (3 × 9.1 g) over a period of 1 h. The reaction mixture was stirred further for 5 h at room temperature. The resulting mixture was then filtered through a pad of Celite[®]/Na₂SO₄ and the filtrate was concentrated under reduced pressure. The residue was distilled from P₂O₅ under reduced pressure (18 mm Hg) at 70 °C to give product **3a** as a colorless oil (27 g, 86%). ¹H NMR (250 MHz, CDCl₃) δ 9.40 (s, 1H), 4.32 (t, *J* = 6.7 Hz, 2H), 1.81-1.63 (m, 2H), 1.51-1.34 (m, 2H), 0.95 (t, *J* = 7.3 Hz, 3H), (lit.^{14d}); ¹³C NMR (63 MHz, CDCl₃) δ 184.0 (CH), 159.6 (C), 66.4 (CH₂), 30.3 (CH₂), 18.9 (CH₂), 13.5 (CH₃); HRMS (ESI-TOF) not stable.

tert-Butyl formyl(vinyl)carbamate 2b

To a solution of *N*-vinylformamide **2a** (4.18 mL, 60 mmol, 1 equiv.) in THF (200 mL) were added Boc₂O (15.7 g, 72 mmol, 1.2 equiv.) and 4-dimethylaminopyridine (73 mg, 0.6 mmol, 0.01 equiv.). The reaction mixture was stirred for 22 h under argon at room temperature then the solvent was removed under reduced pressure. The residue was purified by flash chromatography (20:80 EtOAc/Petroleum ether) to give product **2b** as a colorless liquid (9.55 g, 93%). R_f (5:95 EtOAc/Petroleum ether): 0.46; IR v 2982, 1740, 1709, 1349, 1297, 1249, 1140, 1053; ¹H NMR (250 MHz, CDCl₃) δ 9.23 (s, 1H), 6.57 (dd, *J* = 16.2,

The Journal of Organic Chemistry

9.7 Hz, 1H), 5.65 (dd, *J* = 16.2, 1.2 Hz, 1H), 5.01 (d, *J* = 9.7 Hz, 1H), 1.54 (s, 9H), (lit.²²); ¹³C NMR (63 MHz, CDCl₃) δ 162.1 (CH), 151.3 (C), 126.1 (CH), 107.8 (CH₂), 84.8 (C), 27.8 (3CH₃); HRMS (ESI-TOF) not stable.

tert-Butyl vinylcarbamate 2c

To a solution of *tert*-butyl formyl(vinyl)carbamate **2b** (7.16 g, 41.9 mmol, 1 equiv.) in THF (25 mL) at 0 °C was added carefully over a 20 min period a 2 M aqueous solution of NaOH (25 ml, 50 mmol, 1.2 equiv.). The reaction mixture was left at 0 °C for a further 10 min, then stirred at room temperature for 2.5 h. The reaction mixture was diluted with water (20 mL) and extracted with tBuOMe (4 × 20 mL). The combined organic phases were then washed with water then brine. The resulting organic solution was dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was then recrystallized at -20 °C overnight in pentane to give product **2c** as a white solid (5.87 g, 98%). R_f (50:50 EtOAc/Petroleum ether): 0.33; Mp: 65-67 °C (lit.²² Mp: 67-68 °C); IR v 3324, 2986, 2974, 1690, 1646, 1369, 1250, 1152, 1083, 977; ¹H NMR (360 MHz, CDCl₃) δ 6.75-6.58 (m, 1H), 6.29 (br. s, 1H), 4.40 (d, *J* = 15.7 Hz, 1H), 4.21 (d, *J* = 8.2 Hz, 1H), 1.47 (s, 9H), (lit.²²); ¹³C NMR (90 MHz, CDCl₃) δ 152.9 (C), 130.2 (CH), 92.0 (CH₂), 80.4 (C), 28.3 (3CH₃); HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₇H₁₄NO₂ 144.1019; Found 144.1021.

n-Butyl 3-formamidooxetane-2-carboxylate 5a/b

General procedure **A** was applied for the photochemical reaction between *n*-butyl glyoxylate **3a** (13.0 g, 100 mmol) and *N*-vinylformamide **2a** (14.2 g, 13.9 mL, 200 mmol) in MeCN (1 L). Flash chromatography (70:30 EtOAc/Petroleum ether) gave a mixture of two inseparable diastereoisomers **5a** and **5b** (d.r. 50/50) as a colorless oil (9.17 g, 46%). R_f (70:30 EtOAc/Petroleum ether): 0.32; IR v 3675, 3309, 2964, 2901, 1735, 1669, 1394, 1212, 1042; HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for C₉H₁₅NO₄Na 224.0899; Found 224.0891. From the mixture, the following NMR data was deduced. **5a**: ¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 6.83-6.73 (m, 1H), 5.56-5.41 (m, 1H), 5.29 (d, *J* = 7.8 Hz, 1H), 4.97 (dd, *J* = 7.6, 6.9 Hz, 1H), 4.66 (t, *J* = 6.6 Hz, 1H), 4.21 (t, *J* = 6.7 Hz, 2H), 1.71-1.55 (m, 2H), 1.44-1.29 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (90 MHz, CDCl₃) δ 170.1 (C), 161.0 (CH), 83.2 (CH), 76.7 (CH₂), 65.4 (CH₂), 44.1 (CH), 30.5 (CH₂), 18.9 (CH₂), 13.5 (CH₃); **5b**: ¹H NMR (300 MHz, CDCl₃) δ 8.16 (s, 1H), 6.71-6.62 (m, 1H), 5.14- 5.01 (m, 2H), 4.84 (t, *J* = 6.9 Hz, 1H), 4.56 (t, *J* = 6.3 Hz, 1H), 4.19 (t, *J* = 6.6 Hz, 2H), 1.69-1.55 (m, 2H), 1.42-1.28 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (90 MHz, CDCl₃) δ 170.3 (C), 161.2 (CH), 83.9 (CH), 75.6 (CH₂), 65.5 (CH₂), 46.5 (CH), 30.4 (CH₂), 18.9 (CH₂), 13.6 (CH₃).

Methyl 3-formamidooxetane-2-carboxylate 6a/b

General procedure **A** was applied for the photochemical reaction between methyl glyoxylate **3b** (924 mg, 10.5 mmol) and *N*-vinylformamide **2a** (1.49 g, 1.46 mL, 21 mmol) in MeCN (200 mL). Flash chromatography (90:10 EtOAc/Petroleum ether) gave a mixture of two inseparable diastereoisomers **6** (d.r. 50/50) as a white solid (622 mg, 37%). R_f (90:10 EtOAc/Petroleum ether): 0.21; IR v 3676, 3299, 2987, 2971, 2961, 2901, 1735, 1670, 1522, 1388, 1230, 1178, 1042, 993; HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for C₆H₉NO₄Na 182.0424; Found 182.042. From the mixture, the following NMR data was deduced. **6a**: ¹H NMR (360 MHz, CDCl₃) δ 7.99 (s, 1H), 7.70 (d, *J* = 8.4 Hz, 1H), 5.36-5.25 (m, 1H), 5.21 (d, *J* = 7.8 Hz, 1H), 4.81 (t, *J* = 7.2 Hz, 1H), 4.55 (t, *J* = 6.6 Hz, 1H), 3.64 (s, 3H); ¹³C NMR (90 MHz, CDCl₃) δ 8.04 (s, 1H), 7.95 (d, *J* = 9.0 Hz, 1H), 5.02-4.93 (m, 2H), 4.69 (t, *J* = 6.8 Hz, 1H), 4.48 (t, *J* = 6.2 Hz, 1H), 3.66 (s, 3H); ¹³C NMR (90 MHz, CDCl₃) δ 170.6 (C), 161.4 (CH), 83.5 (CH), 75.4 (CH₂), 52.3 (CH₃), 46.2 (CH).

tert-Butyl 3-formamidooxetane-2-carboxylate 7a/b

General procedure **A** was applied for the photochemical reaction between *tert*-butyl glyoxylate **3c** (1.06 g, 8.18 mmol) and *N*-vinylformamide **2a** (1.16 g, 1.14 mL, 16.4 mmol) in MeCN (200 mL). Flash chromatography (85:15 EtOAc/Petroleum ether) gave a mixture of two inseparable and indistinguishable diastereoisomers (d.r. 54/46) as a colorless oil (557 mg, 34%). R_f (90:10 EtOAc/Petroleum ether): 0.31; IR v 3311, 2977, 2932, 2899, 2854, 1731, 1684, 1369, 1248, 1154, 1027; ¹H NMR (360 MHz, CDCl₃) δ 8.12 (s, 1H), 8.11 (s, 1H), 7.65 (d, *J* = 7.9 Hz, 1H), 7.54 (d, *J* = 8.7 Hz, 1H), 5.41-5.30 (m, 1H), 5.15 (d, *J* = 7.6 Hz, 1H), 5.07-4.95 (m, 1H), 4.93-4.85 (m, 2H), 4.75 (t, *J* = 7.0 Hz, 1H), 4.58 (t, *J* = 6.4 Hz, 1H), 4.49 (t, *J* = 6.5 Hz, 1H), 1.43 (s, 9H), 1.41 (s, 9H); ¹³C NMR (90 MHz, CDCl₃) δ 169.5 (C), 169.2 (C), 161.1 (CH), 161.0 (CH), 84.3 (CH), 83.2 (CH), 83.0 (C), 82.7 (C), 76.4 (CH₂), 75.4 (CH₂), 46.5 (CH), 44.3 (CH), 28.1 (3CH₃), 27.9 (3CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₉H₁₅NO₄Na 224.0893; Found 224.0889.

Butyl 3-(N-(tert-butoxycarbonyl)formamido)oxetane-2-carboxylate 8a and 8b

General procedure **A** was applied for the photochemical reaction between *n*-butyl glyoxylate **3a** (2.44 g, 18.8 mmol) and enecarbamate **2b** (6.42 g, 37.5 mmol) in MeCN (1 L). Flash chromatography (70:20:10 Petroleum ether/CH₂Cl₂/EtOAc) of the crude mixture of diastereoisomers **8** (d.r. 48/52 by NMR analysis) gave *cis* diastereoisomer **8a** (1.00 g, 18%) and *trans* diastereoisomer **8b** (1.53 g, 27%) as colorless oils (2.53 g, 45%). **8a**: R_f (70:20:10 Petroleum ether/CH₂Cl₂/EtOAc): 0.22; IR v 2963, 2936, 1739, 1696, 1348, 1299, 1147, 1078, 1024; ¹H NMR (360 MHz, CDCl₃) δ 9.06 (s, 1H), 5.46 (dd, *J* = 16.3, 8.3 Hz, 1H), 5.22 (dd, *J* = 7.7, 6.2 Hz, 1H), 5.17 (d, *J* = 8.6 Hz, 1H), 4.81 (dd, *J* = 8.4, 6.2 Hz, 1H), 4.12 (t, *J* = 6.8 Hz, 2H), 1.66-1.57 (m, 2H), 1.52 (s, 9H), 1.40-1.29 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (63 MHz, CDCl₃) δ 169.3(C),

The Journal of Organic Chemistry

163.0 (CH), 151.5 (C), 85.6 (C), 81.4 (CH), 74.3 (CH₂), 65.2 (CH₂), 47.1 (CH), 30.5 (CH₂), 28.0 (3CH₃), 19.1 (CH₂), 13.7 (CH₃); HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for C₁₄H₂₃NO₆Na 324.1418; Found 324.1433. **8b**: R_f (70:20:10 Petroleum ether/CH₂Cl₂/EtOAc): 0.35; IR v 2963, 2936, 1740, 1698, 1369, 1248, 1218, 1148, 1049; ¹H NMR (250 MHz, CDCl₃) δ 9.13 (s, 1H), 5.43 (d, *J* = 7.1 Hz, 1H), 5.34 (dd, *J* = 15.2, 7.2 Hz, 1H), 4.93 (t, *J* = 6.7 Hz, 1H), 4.73 (dd, *J* = 8.1, 6.2 Hz, 1H), 4.21 (q, *J* = 6.6 Hz, 2H), 1.72-1.59 (m, 2H), 1.57 (s, 9H), 1.47-1.31 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (63 MHz, CDCl₃) δ 170.0 (C), 162.9 (CH), 151.4 (C), 85.7 (C), 81.5 (CH), 73.0 (CH₂), 65.4 (CH₂), 48.4 (CH), 30.6 (CH₂), 28.1 (3CH₃), 19.0 (CH₂), 13.7 (CH₃); HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for C₁₄H₂₃NO₆Na 324.1418; Found 324.1423.

To a solution of Boc₂O (17.1 g, 78.5 mmol, 1.5 equiv.) and *n*-butyl 3-formamidooxetane-2-carboxylate **5a/b** (d.r. 50/50; 10.5 g, 52.3 mmol, 1 equiv.) in THF (400 mL) was added the 4-dimethylaminopyridine (64 mg, 0.52 mmol, 0.01 equiv.). The reaction mixture was stirred under argon at room temperature for 24 h. The solvent was removed under reduced pressure. Flash chromatography of the residue (70:20:10 Petroleum ether/CH₂Cl₂/EtOAc) gave *cis* diastereoisomer **8a** (5.75 g, 37%) and *trans* diastereoisomer **8b** (7.61 g, 48%) as colorless oils. Spectral data of **8a** and **8b** were identical to those described above.

Butyl 3-(tert-butoxycarbonylamino)oxetane-2-carboxylate 10a/b

General procedure **A** was applied for the photochemical reaction between *n*-butyl glyoxylate **3a** (2.10 g, 16.1 mmol) and enecarbamate **2c** (4.61 g, 32.3 mmol) in MeCN (200 mL). Flash chromatography (20:80 EtOAc/Petroleum ether) gave the mixture of two inseparable and indistinguishable diastereoisomers **10** (d.r. 50/50) as a colorless oil (1.79 g, 41%). R_f (50:50 EtOAc/Petroleum ether): 0.33; IR v 3350, 2965, 1696, 1367, 1249, 1161, 1062; ¹H NMR (360 MHz, CDCl₃) δ 5.58-5.05 (m, 4H), 4.99-4.45 (m, 6H), 4.22-4.04 (m, 4H), 1.66-1.50 (m, 4H), 1.44-1.27 (m, 22H), 0.92-0.83 (m, 6H); ¹³C NMR (90 MHz, CDCl₃) δ 170.3 (C), 154.5 (2C), 84.9 (CH), 84.2 (CH), 80.3 (2C), 78.3 (CH₂), 76.5 (CH₂), 65.3 (CH₂), 65.1 (CH₂), 49.4 (CH), 46.7 (CH), 30.7 (CH₂), 30.6 (CH₂), 28.4 (3CH₃), 28.3 (3CH₃), 19.1 (CH₂), 19.0 (CH₂), 13.7 (2CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₃H₂₃NO₅Na 296.1468; Found 296.1462.

cis-3-(tert-Butoxycarbonylamino)oxetane-2-carboxylic acid 9a

General procedure **B** was applied on compound **8a** (1.01 g, 3.36 mmol) using K₂CO₃ (1.39 g, 10.1 mmol) in MeOH (45 mL) to give product **9a** as a white solid (703 mg, 97%). Mp: 153-155 °C; IR v 3285, 2977, 1749, 1654, 1568, 1288, 1202, 1165, 1066; ¹H NMR (250 MHz, CD₃OD) δ 5.17 (d, *J* = 7.8 Hz, 1H), 5.06-4.94 (m, 1H), 4.83-4.77 (m, 1H), 4.58 (t, *J* = 6.6 Hz, 1H), 1.39 (s, 9H); ¹³C NMR (63 MHz, CD₃OD) δ 173.1 (C), 157.2 (C), 85.5 (CH), 80.7 (C), 77.0 (CH₂), 48.3 (CH), 28.6 (3CH₃); HRMS (ESI-TOF) m/z: [M – H]⁻ Calcd for C₉H₁₄NO₅ 216.0877; Found 216.0882.

trans-3-(tert-Butoxycarbonylamino)oxetane-2-carboxylic acid 9b

General procedure **B** was applied on compound **8b** (1.00 g, 3.33 mmol) using K₂CO₃ (1.38 g, 10.0 mmol) in MeOH (45 mL) to give product **9b** as a white solid (687 mg, 96%). Mp: 124-125 °C; IR v 3363, 2981, 1724, 1693, 1533, 1169, 1055; ¹H NMR (300 MHz, CD₃OD) δ 4.96 (d, *J* = 4.8 Hz, 1H), 4.72-4.60 (m, 2H), 4.53-4.46 (m, 1H), 1.41 (s, 9H); ¹³C NMR (90 MHz, CD₃OD) δ 173.9 (C), 157.0 (C), 85.6 (CH), 80.9 (C), 76.9 (CH₂), 50.7 (CH), 28.6 (3CH₃); HRMS (ESI-TOF) m/z: [M – H]⁻ Calcd for C₉H₁₄NO₅ 216.0877; Found 216.0872.

tert-Butyl (2*R*,3*S*)-2-[(*R*)-2-oxo-4-phenyloxazolidine-3-carbonyl]oxetan-3-yl carbamate 12ac1 and *tert*butyl (2*S*,3*R*)-2-[(*R*)-2-oxo-4-phenyloxazolidine-3-carbonyl]oxetan-3-yl carbamate 12ac2

General procedure C was applied using racemic Boc-oxetin 9a (1.30 g, 5.99 mmol) and triethylamine (1.0 mL, 7.19 mmol) in THF (60 mL), pivaloyl chloride (1.10 mL, 8.98 mmol), (R)-4-phenyloxazolidin-2-one 11c (1.56 g, 9.58 mmol) in THF (29 mL) and *n*-BuLi (1.51 M solution in hexane; 6.35 mL, 9.58 mmol). Flash chromatography (80:20 Et₂O/Petroleum ether then 75:25 Et₂O/EtOAc) gave diastereoisomer **12ac1** as white powder (764 mg, 35%) and diastereoisomer **12ac2** as a white powder (731 mg, 34%). In addition, unreacted **9a** was recovered (190 mg, 15%). **12ac1**: R_f (80:20, Et₂O/Petroleum ether): 0.20; Mp: 84-85 °C; [α]_D²⁷ –76 (c 0.5, CHCl₃); IR v 3316, 2977, 1777, 1704, 1383, 1251, 1161, 989; ¹H NMR (360 MHz, CDCl₃) δ 7.44-7.27 (m, 5H), 6.22 (d, J = 7.0 Hz, 1H), 5.47 (dd, J = 8.6, 3.5 Hz, 1H), 5.34-5.13 (m, 2H), 4.90 (t, J = 7.0 Hz, 1H), 4.69 (t, J = 8.8 Hz, 1H), 4.47 (t, J = 5.7 Hz, 1H), 4.35 (dd, J = 8.8, 3.5 Hz, 1H), 1.44 (s, 9H);¹³C NMR (90 MHz, CDCl₃) δ 169.4 (C), 154.3 (C), 153.0 (C), 138.3 (C), 129.3 (2CH), 129.1 (CH), 126.3 (2CH), 85.0 (CH), 80.4 (C), 77.4 (CH₂), 71.1 (CH₂), 57.3 (CH), 48.6 (CH), 28.3 (3CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₈H₂₂N₂O₆Na 385.1370; Found 385.1354. **12ac2:** R_f (80:20, Et₂O/Petroleum ether): 0.09; Mp: 146-148 °C; [α]_D²⁷ +11 (c 0.5, CHCl₃); IR v 3308, 2976, 1793, 1697, 1383, 1206, 1160, 1001; ¹H NMR (360 MHz, CDCl₃) δ 7.46-7.28 (m, 5H), 6.03 (d, J = 7.7 Hz, 1H), 5.40 (dd, J = 8.7, 3.5 Hz, 1H), 5.36 (br. s, 1H), 4.85-4.71 (m, 3H), 4.37 (t, J = 6.8 Hz, 1H), 4.30 (dd, J = 8.9, 3.5 Hz, 1H), 1.46 (s, 9H); ¹³C NMR (63 MHz, CDCl₃) δ 169.6 (C), 154.0 (C), 153.1 (C), 139.0 (C), 129.5 (2CH), 129.0 (CH), 126.2 (2CH), 84.8 (CH), 80.5 (C), 78.1 (CH₂), 71.4 (CH₂), 57.6 (CH), 48.2 (CH), 28.4 (3CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₈H₂₂N₂O₆Na 385.1370; Found 385.1352.

tert-Butyl (2*R*,3*S*)-2-[(4*S*,5*R*)-4-methyl-2-oxo-5-phenyloxazolidine-3-carbonyl]oxetan-3-yl carbamate 12ab1 and *tert*-butyl (2*S*,3*R*)-2-[(4*S*,5*R*)-4-methyl-2-oxo-5-phenyloxazolidine-3-carbonyl]oxetan-3-yl carbamate 12ab2

General procedure **C** was applied using racemic Boc-oxetin **9a** (400 mg, 1.84 mmol) and triethylamine (0.31 mL, 2.21 mmol) in THF (18 mL), pivaloyl chloride (0.34 mL, 2.76 mmol), (4*S*,5*R*)-4-methyl-5-

Page 15 of 22

The Journal of Organic Chemistry

phenyloxazolidin-2-one **11b** (523 mg, 2.95 mmol) in THF (9 mL) and *n*-BuLi (1.37 M solution in hexane; 2.15 mL, 2.95 mmol). Flash chromatography (80:20 Et₂O/Petroleum ether) gave diastereoisomer 12ab1 as a white powder (170 mg, 25%) and diastereoisomer **12ab2** as white powder (182 mg, 26%). Each compound was purified by precipitation from Et₂O solution by slow addition of petroleum ether. In addition, unreacted **9a** was recovered (45 mg, 11%). **12ab1:** R_f (90:10 Et₂O/Petroleum ether): 0.16; Mp: 190-192 °C; [α]_D²⁷ –30 (c 0.5, CHCl₃); IR v 3349, 2981, 1770, 1706, 1356, 1206, 1151, 978; ¹H NMR (250 MHz, CDCl₃) δ 7.48-7.27 (m, 5H), 6.23 (d, J = 7.6 Hz, 1H), 5.77 (d, J = 7.2 Hz, 1H), 5.44-5.24 (m, 1H), 5.20-5.05 (m, 1H), 4.98 (t, J = 7.2 Hz, 1H), 4.90-4.77 (m, 1H), 4.58 (t, J = 6.6 Hz, 1H), 1.41 (s, 9H), 0.96 (d, J = 6.6 Hz, 3H); ¹³C NMR (250 MHz, CDCl₃) δ 169.8 (C), 153.9 (C), 152.2 (C), 133.0 (C), 129.0 (CH), 128.8 (2CH), 125.6 (2CH), 84.9 (CH), 80.8 (C), 80.1 (CH), 77.6 (CH₂), 54.5 (CH), 48.5 (CH), 28.3 (3CH₃), 14.5 (CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₉H₂₄N₂O₆Na 399.1527; Found 399.1510. **12ab2:** R_f (90:10, Et₂O/Petroleum ether): 0.22; Mp: 183-184 °C; [α]_D²⁴ +15 (c 0.25, CHCl₃); IR v 3356, 2984, 2973, 1770, 1711, 1364, 1249, 1216, 1147, 979; ¹H NMR (250 MHz, CDCl₃) δ 7.48-7.27 (m, 5H), 6.28 (d, *J* = 7.5 Hz, 1H), 5.68 (d, J = 7.1 Hz, 1H), 5.49 (br. s, 1H), 5.32-5.14 (m, 1H), 4.95 (t, J = 7.1 Hz, 1H), 4.90-4.75 (m, 1H), 4.55 (t, J = 6.6 Hz, 1H), 1.42 (s, 9H), 0.92 (d, J = 6.6 Hz, 3H); ¹³C NMR (250 MHz, CDCl₃) δ 169.5 (C), 154.4 (C), 152.4 (C), 133.0 (C), 129.0 (CH), 128.8 (2CH), 125.7 (2CH), 85.2 (CH), 80.5 (C), 80.3 (CH), 77.2 (CH₂), 54.7 (CH), 48.8 (CH), 28.3 (3CH₃), 14.7 (CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₉H₂₄N₂O₆Na 399.1527; Found 399.1533.

tert-Butyl (2*R*,3*R*)-2-[(*S*)-4-benzyloxymethyl-2-oxooxazolidine-3-carbonyl]oxetan-3-yl carbamate 12ba1 and *tert*-butyl (2*S*,3*S*)-2-[(*S*)-4-benzyloxymethyl-2-oxooxazolidine-3-carbonyl]oxetan-3-yl carbamate 12ba2

General procedure **C** was applied using racemic Boc-*epi*-oxetin **9b** (250 mg, 1.15 mmol) and triethylamine (0.19 mL, 1.38 mmol) in THF (12 mL), pivaloyl chloride (0.21 mL, 1.73 mmol), (S)-4- (benzyloxymethyl)oxazolidin-2-one **11a** (382 mg, 1.84 mmol) in THF (6 mL) and *n*-BuLi (1.55 M solution in hexane; 1.19 mL, 1.84 mmol). Flash chromatography (50:50 then 60:40 EtOAc/Petroleum ether) gave the diastereoisomer **12ba1** as a colorless oil (130 mg, 28%) and diastereoisomer **12ba2** as a white solid (177 mg, 38%). The latter compound was purified by precipitation from Et₂O solution by slow addition of petroleum ether. In addition, unreacted **9b** was recovered (60 mg, 24 %). **12ba1:** R_f (55:45 EtOAc/Petroleum ether): 0.42; $[\alpha]_{p}^{26}$ +46 (c 0.5, CHCl₃); IR v 3349, 2967, 1779, 1702, 1365, 1260, 1160, 1092, 1014; ¹H NMR (360 MHz, CDCl₃) δ 7.40-7.28 (m, 5H), 5.84 (d, *J* = 5.5 Hz, 1H), 5.67 (br. s, 1H), 4.86-4.75 (m, 1H), 4.67-4.51 (m, 5H), 4.49-4.43 (m, 2H), 3.83 (dd, *J* = 9.8, 4.9 Hz, 1H), 3.64 (dd, *J* = 9.8, 1.8 Hz, 1H), 1.43 (s, 9H); ¹³C NMR (90 MHz, CDCl₃) δ 169.6 (C), 155.2 (C), 153.9 (C), 137.3 (C), 128.7 (2CH), 128.2 (CH), 127.9 (2CH), 83.2 (CH), 80.2 (C), 76.1 (CH₂), 73.6 (CH₂), 67.5 (CH₂), 67.0 (CH₂), 53.6 (CH), 50.3 (CH),

28.4 (3CH₃); HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for C₂₀H₂₆N₂O₇Na 429.1632; Found 429.1631. **12ba2**: R_f (55:45, EtOAc/Petroleum ether): 0.35; Mp: 124-126 °C; $[\alpha]_D^{26}$ +41 (c 0.5, CHCl₃); IR v 3351, 2980, 2884, 1775, 1710, 1691, 1384, 1247, 1204, 1165, 986; ¹H NMR (360 MHz, CDCl₃) δ 7.39-7.22 (m, 5H), 5.97 (d, *J* = 5.8 Hz, 1H), 5.75 (br. s, 1H), 4.84-4.66 (m, 2H), 4.62-4.36 (m, 6H), 3.79 (dd, *J* = 9.9, 4.6 Hz, 1H), 3.59 (d, *J* = 9.9 Hz, 1H), 1.44 (s, 9H); ¹³C NMR (63 MHz, CDCl₃) δ 169.7 (C), 155.1 (C), 153.7 (C), 137.3 (C), 128.5 (2CH), 128.0 (CH), 127.6 (2CH), 84.2 (CH), 80.2 (C), 75.4 (CH₂), 73.3 (CH₂), 67.5 (CH₂), 66.5 (CH₂), 53.7 (CH), 50.1 (CH), 28.3 (3CH₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₀H₂₆N₂O₇Na 429.1632; Found 429.1611.

tert-Butyl (2*R*,3*R*)-2-[(4*S*,5*R*)-4-methyl-2-oxo-5-phenyloxazolidine-3-carbonyl]oxetan-3-yl carbamate 12bb1 and *tert*-butyl (2*S*,3*S*)-2-[(4*S*,5*R*)-4-methyl-2-oxo-5-phenyloxazolidine-3-carbonyl]oxetan-3-yl carbamate 12bb2

General procedure C was applied using racemic Boc-epi-oxetin 9b (150 mg, 0.69 mmol) and triethylamine (0.12 mL, 0.83 mmol) in THF (7 mL), pivaloyl chloride (0.13 mL, 1.04 mmol), (4S,5R)-4methyl-5-phenyloxazolidin-2-one 11b (196 mg, 1.11 mmol) in THF (3.5 mL) and n-BuLi (1.52 M solution in hexane; 0.73 mL, 1.11 mmol). Flash chromatography (80:20, Et₂O/Petroleum ether) gave the single diastereoisomer **12bb2** as a white solid (45 mg, 17%) and a mixture of diasteroisomers **12bb1** and **12bb2** as a white solid (44 mg, 17%). In addition, unreacted **9b** was recovered (34 mg, 23%). **12bb2:** R_f (80:20 Et₂O/Petroleum ether): 0.26; Mp: 147-148 °C; $[\alpha]_D^{27}$ –50 (c 0.38, CHCl₃); IR v 3380, 2990, 2886, 1795, 1713, 1346, 1256, 1247, 1197, 1161, 989; ¹H NMR (360 MHz, CDCl₃) δ 7.46-7.28 (m, 5H), 6.10 (d, J = 3.8 Hz, 1H), 5.81 (d, J = 7.1 Hz, 1H), 5.66 (d, J = 5.8 Hz, 1H), 4.89-4.74 (m, 3H), 4.64-4.55 (m, 1H), 1.44 (s, 9H), 0.94 (d, J = 6.6 Hz, 3H); ¹³C NMR (90 MHz, CDCl₃) δ 169.6 (C), 155.3 (C), 153.1 (C), 133.0 (C), 129.0 (CH), 128.8 (2CH), 125.7 (2CH), 84.8 (CH), 80.5 (C), 80.2 (CH), 75.3 (CH₂), 55.0 (CH), 50.3 (CH), 28.3 (3CH₃), 14.6 (CH₃); HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for C₁₉H₂₄N₂O₆Na 399.1527; Found 399.1511. From the diastereoisomeric mixture, the following NMR data was deduced. **12bb1:** ¹H NMR (400 MHz, CDCl₃) δ 7.46-7.28 (m, 5H), 5.94 (d, J = 5.4 Hz, 1H), 5.76 (d, J = 7.5 Hz, 1H), 5.63 (d, J = 3.5 Hz, 1H), 4.89-4.75 (m, 2H), 4.73-4.64 (m, 1H), 4.64-4.55 (m, 1H), 1.47 (s, 9H), 0.98 (d, J = 6.6 Hz, 3H); ¹³C NMR (63 MHz, CDCl₃) δ 169.3 (C), 154.9 (C), 152.5 (C), 132.8 (C), 128.4 (CH), 128.3 (2CH), 125.4 (2CH), 84.1 (CH), 79.7 (CH), 79.4 (C), 74.9 (CH₂), 54.0 (CH), 49.7 (CH), 27.9 (3CH₃), 14.0 (s, CH₃).

(2R,3S)-3-(tert-Butoxycarbonylamino)oxetane-2-carboxylic acid (–)-9a

General procedure **D** was applied on compound **12ac1** (78 mg, 0.22 mmol) in a 1:4 mixture of water and THF (5 mL) with a 35% w/w solution of H_2O_2 (0.037 mL, 0.43 mmol) and LiOH·H₂O (18 mg, 0.43 mmol) in

The Journal of Organic Chemistry

water (0.8 mL), to give (–)-9a (38 mg, 82%). $[\alpha]_D^{27}$ –31 (c 0.5, CHCl₃). Spectral data were identical to those obtained for racemic material described above.

General procedure **B** was applied on compound (**2***R*,**3***S***)**-**8a** (1.51 g, 5.0 mmol) using K₂CO₃ (2.07 g, 15.0 mmol) in MeOH (65 mL) to give (–)-9a (1.08 g, 99%). $[\alpha]_D^{26}$ –32 (c 0.5, CHCl₃). Spectral data were identical to those described above.

(2S,3R)-3-(tert-Butoxycarbonylamino)oxetane-2-carboxylic acid (+)-9a

General procedure **D** was applied on compound **12ac2** (62 mg, 0.17 mmol) in a 1:4 mixture of water and THF (4 mL) with a 35% w/w solution of H_2O_2 (0.030 mL, 0.34 mmol) and LiOH· H_2O (14 mg, 0.34 mmol) in water (0.5 mL), to give **(+)-9a** (29 mg, 78%). $[\alpha]_D^{27}$ +32 (c 0.5, CHCl₃). Spectral data were identical to those described for racemic material above.

General procedure **D** was applied on compound **12ab2** (39 mg, 0.10 mmol) in a 1:4 mixture of water and THF (2.5 mL) with a 35% w/w solution of H_2O_2 (0.018 mL, 0.21 mmol) and LiOH· H_2O (9 mg, 0.21 mmol) in water (0.4 mL), to give **(+)-9a** (20 mg, 89%). $[\alpha]_D^{27}$ +30 (c 0.5, CHCl₃). Spectral data were identical to those described above.

General procedure **B** was applied on compound **(25,3***R***)-8a** (1.01 g, 3.35 mmol) using K₂CO₃ (1.39 g, 10.1 mmol) in MeOH (45 mL), to give **(+)-9a** (698 mg, 96%). $[\alpha]_D^{25}$ +33 (c 0.5, CHCl₃). Spectral data were identical to those described above.

(2R,3R)-3-(tert-Butoxycarbonylamino)oxetane-2-carboxylic acid (+)-9b

General procedure **D** was applied on compound **12ba1** (140 mg, 0.35 mmol) in a 1:4 mixture of water and THF (10 mL) with a 35% w/w solution of H_2O_2 (0.060 mL, 0.69 mmol) and LiOH· H_2O (29 mg, 0.69 mmol) in water (2 mL), to give **(+)-9b** (75 mg, 99%). [α]_D²⁴ +35 (c 0.5, CHCl₃). Spectral data were identical to those described for racemic material above.

General procedure **B** was applied on compound (**2***R***,3***R***)-8b** (1.28 g, 4.25 mmol) using K₂CO₃ (1.76 g, 12.8 mmol) in MeOH (55 mL) to give (+)-9b (890 mg, 97%). $[\alpha]_D^{26}$ +31 (c 0.5, CHCl₃). Spectral data were identical to those described above.

(25,35)-3-(tert-Butoxycarbonylamino)oxetane-2-carboxylic acid (-)-9b

General procedure **D** was applied on compound **12ba2** (59 mg, 0.15 mmol) in a 1:4 mixture of water and THF (3 mL) with a 35% w/w solution of H_2O_2 (0.025 mL, 0.29 mmol) and LiOH· H_2O (12 mg, 0.29 mmol) in water (0.5 mL), to give (–)-9b (31 mg, 97%). $[\alpha]_D^{26}$ –36 (c 0.5, CHCl₃) {lit.⁴ $[\alpha]_D^{25}$ –61.2 (c 0.5, CDCl₃)}. Spectral data were identical to those described for racemic material above, and in the literature.⁴

General procedure **D** was applied on compound **12bb2** (76 mg, 0.20 mmol) in a 1:4 mixture of water and THF (5 mL) with a 35% w/w solution of H_2O_2 (0.035 mL, 0.40 mmol) and LiOH· H_2O (17 mg, 0.40 mmol) in water (1 mL), to give (–)-9b (38 mg, 87%). [α]_D²² –33 (c 0.5, CHCl₃). Spectral data were identical to those described above.

General procedure **B** was applied on compound **(25,35)-8b** (1.02 g, 3.40 mmol) and K₂CO₃ (1.41 g, 10.2 mmol) in MeOH (45 mL), to give **(–)-9b** (710 mg, 96%). $[\alpha]_D^{25}$ –32 (c 0.5, CHCl₃). Spectral data were identical to those described above.

(2R,3S)-3-aminooxetane-2-carboxylic acid (+)-1a

General procedure **E** was applied on (2R,3S)-Boc-oxetin (87 mg, 0.40 mmol) in CH₂Cl₂ (6 mL) with trifluoroacetic acid (0.460 mL, 6.02 mmol) to give (2R,3S)-oxetin **(+)-1a** (45 mg, 96%). Mp: 199-201 °C (lit.² Mp: 185-190 °C); $[\alpha]_D^{26}$ +54 (c 0.18, H₂O) {lit.² $[\alpha]_D^{25}$ +56.4 (c 1.0, H₂O)}; IR v 3117, 2986, 2895, 1636, 1618, 1555, 1410, 1378 1297, 1007, 952; ¹H NMR (360 MHz, D₂O) δ 5.13 (d, *J* = 6.9 Hz, 1H), 4.88-4.81 (m, 1H), 4.46-4.35 (m, 2H), (lit.²); ¹³C NMR (90 MHz, D₂O) δ 175.2 (C), 81.1 (CH), 72.9 (CH₂), 47.4 (CH), (lit.²); HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₄H₈NO₃ 118.0499; Found 118.0501.

(2S,3R)-3-aminooxetane-2-carboxylic acid (-)-1a

General procedure **E** was applied on (2S,3R)-Boc-oxetin **(+)-9a** (128 mg, 0.59 mmol) in CH₂Cl₂ (9 mL) with trifluoroacetic acid (0.677 mL, 8.85 mmol) to give (2S,3R)-oxetin **(-)-1a** (67 mg, 97%). Mp: 199-201 °C (lit.² Mp: 185-190 °C); $[\alpha]_D^{27}$ –54 (c 0.2, H₂O) {lit.² $[\alpha]_D^{21}$ –56.0 (c 1, H₂O)}; IR v 3117, 2986, 2895, 1636, 1618, 1555, 1410, 1378 1297, 1007, 952; ¹H NMR (360 MHz, D₂O) δ 5.13 (d, *J* = 6.9 Hz, 1H), 4.88-4.81 (m, 1H), 4.46-4.35 (m, 2H), (lit.²); ¹³C NMR (90 MHz, D₂O) δ 174.9 (C), 80.3 (CH), 72.2 (CH₂), 47.3 (CH), (lit.²); HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₄H₈NO₃ 118.0499; Found 118.0498.

(2R,3R)-3-aminooxetane-2-carboxylic acid (+)-1b

General procedure **E** was applied on (2R,3R)-Boc-*epi*-oxetin **(+)**-**9b** (130 mg, 0.60 mmol) in CH₂Cl₂ (9 mL) with trifluoroacetic acid (0.688 mL, 8.99 mmol) to give (2R,3R)-*epi*-oxetin **(+)**-**1b** (68 mg, 97%). Mp: 182-183 °C; $[\alpha]_D^{27}$ +13 (c 0.5, H₂O) {lit.² $[\alpha]_D^{21}$ +13.7 (c 1, H₂O)}; IR v 3663, 2971, 2903, 1565, 1392, 1297, 946, 928; ¹H NMR (250 MHz, D₂O) δ 4.91 (t, *J* = 5.2 Hz, 1H), 4.72-4.60 (m, 1H), 4.56-4.45 (m, 1H), 4.26-4.14 (m, 1H), (lit.²); ¹³C NMR (90 MHz, D₂O) δ 176.8 (C), 83.1 (CH), 72.0 (CH₂), 49.7 (CH), (lit.²); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₄H₇NO₃Na 140.0318; Found 140.0321.

(2S,3S)-3-aminooxetane-2-carboxylic acid (-)-1b

Page 19 of 22

The Journal of Organic Chemistry

General procedure **E** was applied on (2*S*,3*S*)-Boc-*epi*-oxetin (–)-9**b** (108 mg, 0.5 mmol in CH₂Cl₂ (7.5 mL) with trifluoroacetic acid (0.57 mL, 7.46 mmol) to give (2*S*,3*S*)-*epi*-oxetin (–)-1**b** (58 mg, 99%). Mp: 182-183 °C; $[\alpha]_D^{26}$ –12 (c 0.5, H₂O) {lit.² $[\alpha]_D^{15}$ –12 (c 1, H₂O); lit.⁴ $[\alpha]_D^{25}$ –13.6 (c 1, H₂O)}; IR v 3663, 2971, 2903, 1565, 1392, 1297, 946, 928; ¹H NMR (250 MHz, D₂O) δ 4.91 (virt.t, *J* = 5.2 Hz, 1H), 4.72-4.60 (m, 1H), 4.56-4.45 (m, 1H), 4.26-4.14 (m, 1H), (lit.^{2,4}); ¹³C NMR (90 MHz, D₂O) δ 176.8 (C), 83.1 (CH), 72.0 (CH₂), 49.7 (CH), (lit.^{2,4}); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₄H₇NO₃Na 140.0318; Found 140.0320.

Enantiomeric separation of 8a

Separation was performed using a Lux Cellulose-1 column (250 mm × 10 mm; particle size 5 µm). The HPLC system was operated with 80:20 hexane/*iso*-propanol as mobile phase flowing at a rate of 5 mL·min⁻¹. The mobile phase and the column were thermostated at 20 ± 2 °C. Detection was performed at 210 nm with a 15 min run time. Sample solutions were in *iso*-propanol (500 mg·mL⁻¹), injection volume 100 µL. (2*R*,3*S*)-8a: retention time: 10.0 min; $[\alpha]_D^{26}$ –20 (c 0.5, CHCl₃); spectral data were identical to those reported above. (2*S*,3*R*)-8a: retention time: 7.0 min; $[\alpha]_D^{26}$ +21 (c 0.5, CHCl₃). Spectral data were identical to those reported for racemic material above.

Enantiomeric separation of 8b

Separation was performed using a Lux Cellulose-2 column (250 mm × 10 mm; particle size 5 µm). The HPLC system was operated with 80:20 hexane/ethanol as mobile phase flowing at a rate of 5 mL·min⁻¹. The mobile phase and the column were thermostated at 20 ± 2 °C. Detection was performed at 210 nm with a 15 min run time. Sample solutions were in ethanol (500 mg·mL⁻¹), injection volume 75 µL. (2*R*,3*R*)-8b: retention time: 11.9 min; $[\alpha]_D^{25}$ –3 (c 1.5, CHCl₃); spectral data were identical to those reported above. (2*S*,3*S*)-8b: retention time: 10.0 min; $[\alpha]_D^{25}$ +3 (c 1.5, CHCl₃). Spectral data were identical to those reported for racemic material above.

Associated content

Supporting Information

Copies of ¹H and ¹³C NMR spectra, crystallographic data for the compounds **12ab2** and **12bb2** (respectively CCDC 1491706 and CCDC 1491705) and chiral HPLC chromatograms are presented in the Electronic Supporting Information. The ESI and crystallographic data in CIF are available free of charge on the ACS Publications website at <u>http://pubs.acs.org/</u>.

Author information

Corresponding Authors

* E-mail: <u>david.aitken@u-psud.fr</u>

Notes

The authors declare no competing financial interest.

Acknowledgments

A. F. K. is grateful to the Municipality of Dair Kanoun Al-Nahr, Lebanon, for the award of a doctoral research scholarship, and warmly thanks Dr O. Yazbeck of the Lebanese University for help and professional council. S. S. R. acknowledges the award of a Fellowship by the Institut Français d'Egypte and the Science and Technology Development Fund in Egypt. For financial support allowing equipment acquisition, we thank the French ANR (project 2011-INTB-1003-01) and Université Paris Sud (AAP-Attractivité 2013).

References

- 1 Ōmura, S.; Murata, M.; Imamura, N.; Iwai, Y.; Tanaka, H. J. Antibiot. **1984**, 37, 1324-1332.
- 2 Kawahata, Y.; Takatsuto, S.; Ikekawa, N.; Murata, M.; Ōmura, S. *Chem. Pharm. Bull.* **1986**, *34*, 3102-3110.
- 3 Bach, T.; Schröder, J. *Liebigs Ann*. **1997**, 2265-2267.
- 4 Blauvelt, M. L.; Howell, A. R. J. Org. Chem. 2008, 73, 517-521.
- (a) Mahal, A. *Eur. J. Chem.* 2015, *6*, 357-366. (b) Malapit, C. A.; Howell, A. R. *J. Org. Chem.* 2015, *80*, 8489-8495. (c) Burkhard, J. A.; Wuitschik, G.; Rogers-Evans, M.; Mueller, K.; Carreira, E. M. *Angew. Chem., Int. Ed.* 2010, *49*, 9052–9067.
- 6 (a) Kiss, L.; Fülöp, F. *Chem. Rev.* **2014**, *114*, 1115–1169. (b) Fülöp, F.; Martinek, T. A.; Toth, G. K. *Chem. Soc. Rev.* **2006**, *35*, 323–334.
- For related oxetanyl peptide motifs, see: (a) Sharma, G. V. M.; Venkarateshwarlu, G.; Katukuri, S.;
 Ramakrishna, K. V. S.; Sarma, A. V. S. *Tetrahedron* 2015, *71*, 2158–2167. (b) Powell, N. H.; Clarkson,
 G. J.; Notman, R.; Raubo, P.; Martin, N. G.; Shipman, M. *Chem. Commun.* 2014, *50*, 8797–8800. (c)
 McLaughlin, M.; Yazaki, R.; Fessard, T. C.; Carreira, E. M. *Org. Lett.* 2014, *16*, 4070–4073.
- 8 Claridge, T. D. W.; Goodman, J. M.; Moreno, A.; Angus, D.; Braker, S. F.; Taillefumier, C.; Watterson, M. P.; Fleet, G. W. J. *Tetrahedron Lett.* **2001**, *42*, 4251–4255.
- 9 For reviews of the Paternò-Büchi reaction, see: (a) D'Auria, M. In: *Comprehensive Organic Synthesis (2nd Edition)*; Knochel, P., Molander, G. A., Eds. Elsevier B.V.: Amsterdam, **2014**, Vol. 5, pp. 159–199. (b) D'Auria, M.; Racioppi, R. *Molecules* **2013**, *18*, 11384-11428. (c) Abe, M. In:

The Journal of Organic Chemistry

Handbook of Synthetic Photochemistry; Albini, A., Fagnoni, M., Eds. Wiley: New York, **2010**; pp. 217–239. (d) Griesbeck, A.G. In: *Synthetic Organic Photochemistry*; Griesbeck, A. G., Mattay, J., Eds. Marcel Dekker: New York, **2005**; pp. 89–139.

- 10 Recent illustrative synthetic applications: (a) Ralph, M.; Ng, S.; Booker-Milburn, K. I. Org. Lett.
 2016, 18, 968-971. (b) Rosenberg, M. G.; Billing, P.; Brecker, L.; Brinker, U. H. J. Org. Chem. 2014, 79, 8786-8799. (c) Valiulin, R. A.; Arisco, T. M.; Kutateladze, A. G. J. Org. Chem. 2011, 76, 1319–1332. (d) Matsumura, K.; Morti, T.; Inoue, Y. J. Org. Chem. 2010, 75, 5461–5469. (e) Vogt, F.; Jödicke, K.; Schröder, J.; Bach, T. Synthesis 2009, 4268-4273. (f) Cho, D. W.; Lee, H.-Y.; Oh, S. W.; Choi, J. H.; Park, H. J.; Mariano, P. S.; Yoon, U. C. J. Org. Chem. 2008, 73, 4539-4547. (g) Iriondo-Alberdi, J.; Perea-Buceta, J. E.; Greaney, M. F. Org. Lett. 2005, 7, 3969-3971. (h) Griesbeck, A. G.; Bondock, S.; Lex. J. Org. Biomol. Chem. 2004, 2, 1113-1115.
- 11 For our own recent applications of [2+2] photochemical cycloadditions, see: (a) Hernvann, F.; Rasore, G.; Declerck, V.; Aitken, D. J. *Org. Biomol. Chem.* **2014**, *12*, 8212-8222. (b) André, V.; Gras, M.; Awada, H.; Guillot, R.; Robin, S.; Aitken, D. J. *Tetrahedron* **2013**, *69*, 3571-3576. (c) Aitken, D. J.; Frongia, A.; Gaucher, X.; Ollivier, J.; Rafique, H.; Sambiagio, C.; Secci, F. *Tetrahedron Lett.* **2013**, *54*, 2825-2827. (d) André, V.; Vidal, A.; Ollivier, J.; Robin, S.; Aitken, D. J. *Tetrahedron Lett.* **2011**, *52*, 1253-1255. (e) Le Liepvre, M.; Ollivier, J.; Aitken, D. J. *Eur. J. Org. Chem.* **2009**, 5953-5962. (f) Gu, X.; Xian, M.; Roy-Faure, S.; Bolte, J.; Aitken, D. J.; Gefflaut, T. *Tetrahedron Lett.* **2006**, *47*, 193-196.
- For Paternò-Büchi reactions implicating *N*-acyl enamines, see ref. 3 and (a) Vogt, F.; Jödicke, K.;
 Schröder, J.; Bach, T. *Synthesis* 2009, 4268-4273. (b) Stafforst, T.; Diederichsen, U. *Eur. J. Org. Chem.* 2007, 681-688. (c) Bach, T.; Bergmann, H.; Brummerhop, H.; Lewis, W.; Harms, K. *Chem. – Eur. J.* 2001, *7*, 4512-4521. (d) Bach, T.; Brummerhop, H.; Harms, K. *Chem. Eur. J.* 2000, *7*, 3838 3848. (e) Bach, T. *Synlett* 2000, 1699-1707, and references therein.
- With the exception of ref. 3, Paternò-Büchi reactions implicating glyoxylate esters have been described only for reactions with furans; see (a) Schreiber, S. L.; Porco, J. A., Jr. J. Org. Chem. 1989, 54, 4721-4723. (b) Schreiber, S. L.; Desmaele, D.; Porco, J. A., Jr. Tetrahedron Lett. 1988, 29, 6689-6692. (c) Koźluk, T.; Zamojski, A. Tetrahedron 1983, 39, 805-810. (d) Jarosz, S.; Zamojski, A. Tetrahedron 1982, 38, 1447-1451.
- (a) Trova, M. P.; Gauuan, P. J. F., Pechulis, A. D.; Bubb, S. M.; Bocckino, S. B.; Crapo, J. D.; Day, B. J. Bioorg. Med. Chem. 2003, 11, 2695-2707. (b) Våbenø, J.; Brisander, M.; Lejon, T.; Luthman, K. J. Org. Chem. 2002, 67, 9186-9191. (c) Hook, J. M. Synthetic Comm. 1984, 14, 83-87. (d) Ottenheijm,

H. C. J.; Liscamp, R. M. J.; van Nispen, S. P. J. M.; Boots, H. A.; Tijhuis, M. W. *J. Org. Chem.* **1981**, *46*, 3273-3283. (e) Kelly, R. T.; Schmidt, T. E.; Haggerty, J. G. *Synthesis* **1972**, 544-545.

- 15 For a related application, see: Kudyba, I.; Raczko, J.; Jurczak, J. *Helv. Chim. Acta.* **2004**, *87*, 1724-1736.
- 16 (a) Hu, S.; Neckers, D. J. Org. Chem. 1996, 61, 6407-6415. (b) Bochet, C. G. J. Chem. Soc., Perkin Trans. 1 2002, 125-142.
- 17 (a) Abe, M. J. Chin. Chem. Soc. 2008, 55, 479-486. (b) Griesbeck, A. G.; Abe, M.; Bondock, S. Acc. Chem. Res. 2004, 37, 919-928. (c) Griesbeck, A. G.; Mauder, H.; Stadtmüller, S. Acc. Chem. Res. 1994, 27, 70-75. (d) Turro, N. J.; Dalton, J. C.; Dawes, K.; Farrington, G.; Hautala, R.; Morton, D.; Niemczyk, M.; Schore, N. Acc. Chem. Res. 1972, 5, 92-101.
- (a) Roy, O.; Faure S.; Aitken, D. J. *Tetrahedron Lett.* 2006, 47, 5981-5987. (b) Aitken, D. J.; Gauzy, C.; Pereira, E. *Tetrahedron Lett.* 2004, 45, 2359-2361.
- 19 Lenz, G. R. Synthesis **1978**, 489-518.
- 20 (a) Declerck, V.; Aitken, D. J. Amino Acids 2011, 41, 587-595. (b) Declerck, V.; Aitken, D. J. J. Org. Chem. 2011, 76, 708-711. (c) Awada, H.; Robin, S.; Guillot, R.; Yazbeck, O.; Naoufal, D.; Jaber, N.; Hachem, A.; Aitken, D. J. Eur. J. Org. Chem. 2014, 7148-7155. (d) Hassoun, A.; Grison, C. M.; Guillot, R.; Boddaert, T.; Aitken, D. J. New J. Chem. 2015, 39, 3270-3279.
- Based on procedures described in the following publications: (a) Tussetschläger, S.; Baro, A.;
 Laschat, S.; Frey, W. Eur. J. Org. Chem. 2007, 5590-5602. (b) Bégis, G.; Cladingboel, D. E.; Jerome,
 L.; Motherwell, W. B.; Sheppard, T. D. Eur. J. Org. Chem. 2009, 1532-1548.
- O'Sullivan, A. C.; Loiseleur, O.; Stierli, D.; Luksch, T.; Pitterna, T. Syngenta Participations AG (Switzerland), PCT Int. Appl. WO/2013/120940A2, 2013. *Chem. Abstr.* 2013, 159, 399013.